Full Name: CureYLD - Curing Youth Leukodystrophies
Headquarters: Boston, Massachusetts, USA
Founded: 2019
Focus: Rare neurological diseases, leukodystrophies, gene therapy
Status: 501(c)(3) nonprofit organization
Website: cureyld.org
CureYLD is a nonprofit biotechnology organization dedicated to finding cures for youth leukodystrophies — a devastating group of rare, progressive genetic disorders that affect the white matter of the brain. Founded in 2019 and headquartered in Boston, Massachusetts, CureYLD bridges the gap between academic research and clinical application, accelerating the development of novel therapies for these devastating neurological conditions.
Leukodystrophies are a class of genetic disorders characterized by abnormal development or destruction of the brain's white matter, which contains the nerve fibers that enable communication between different brain regions. These conditions typically affect children, causing progressive neurological decline including motor impairment, cognitive deterioration, and premature death. With limited treatment options available, CureYLD's mission represents a critical lifeline for affected families.
¶ Mission and Vision
CureYLD's mission is to accelerate the development of curative therapies for leukodystrophies through:
- Funding innovative research in gene therapy, enzyme replacement, and small molecule approaches
- Supporting clinical trials by providing infrastructure and patient recruitment support
- Advocacy and awareness to ensure these rare diseases receive appropriate attention and resources
- Patient and family support programs that provide guidance throughout the diagnostic and treatment journey
The organization collaborates closely with academic medical centers, pharmaceutical partners, and patient advocacy groups to create a comprehensive ecosystem for leukodystrophy research and treatment development.
Leukodystrophies result from genetic mutations that affect the development, maintenance, or function of myelin — the fatty substance that insulates nerve fibers in the central nervous system. When myelin is damaged or fails to develop properly, nerve signal transmission is disrupted, leading to the progressive neurological symptoms characteristic of these disorders.
Metachromatic Leukodystrophy (MLD):
- Caused by mutations in the ARSA gene encoding arylsulfatase A
- Leads to accumulation of sulfatides, a type of lipid, in the brain
- Symptoms include motor regression, cognitive decline, and peripheral neuropathy
- Late-infantile form typically presents between 1-2 years of age
Krabbe Disease (Globoid Cell Leukodystrophy):
- Caused by mutations in the GALC gene encoding galactosylceramidase
- Results in accumulation of psychosine, a toxic metabolite
- Characterized by severe neurodegeneration and developmental regression
- Most severe infantile form presents within the first 6 months of life
Adrenoleukodystrophy (ALD):
- Caused by mutations in the ABCD1 gene affecting peroxisomal transport
- Leads to accumulation of very-long-chain fatty acids (VLCFAs)
- Childhood cerebral ALD is the most severe form, causing rapid neurological decline
- Adrenal insufficiency often accompanies neurological symptoms
Canavan Disease:
- Caused by mutations in the ASPA gene encoding aspartoacylase
- Results in accumulation of N-acetylaspartate (NAA) in the brain
- Characterized by macrocephaly, developmental regression, and hypotonia
- Progressive disease with most patients surviving to adolescence
Gene therapy represents the most promising approach for many leukodystrophies. CureYLD supports programs that deliver functional copies of the defective gene using viral vectors, particularly adeno-associated viruses (AAVs) that can target the central nervous system.
The organization's gene therapy programs include:
- AAV-mediated gene delivery to restore enzyme expression
- Novel vector engineering for improved brain penetration
- Strategies to address immune responses to viral vectors
For diseases where the defective enzyme can be provided exogenously, enzyme replacement therapy (ERT) offers a direct approach to restoring metabolic function. CureYLD supports development of recombinant enzyme products that can cross the blood-brain barrier or be delivered directly to the central nervous system.
Small molecule approaches include:
- Substrate reduction therapy: Reducing the accumulation of toxic metabolites
- Chaperone therapy: Helping misfolded proteins achieve proper conformation
- Anti-inflammatory agents: Addressing neuroinflammation that contributes to disease progression
| Program |
Approach |
Disease |
Development Stage |
Status |
| CY-001 |
Gene therapy (AAV) |
Metachromatic Leukodystrophy |
Preclinical |
IND-enabling studies |
| CY-002 |
Enzyme replacement |
Krabbe Disease |
Discovery |
Lead optimization |
| CY-003 |
Small molecule |
Adrenoleukodystrophy |
Discovery |
Hit-to-lead |
| CY-004 |
Gene therapy |
Canavan Disease |
Research |
Proof of concept |
| CY-005 |
Gene therapy |
Alexander Disease |
Research |
Target validation |
- CY-001: Pre-IND meeting with FDA expected in 2026
- CY-002: Candidate selection expected in 2026
- CY-003: Lead candidate nomination expected in 2027
MLD Natural History Study:
- Understanding disease progression in metachromatic leukodystrophy
- Identifying biomarkers for patient stratification
- ClinicalTrials.gov identifier: (TBD)
ALD Natural History Study:
- Characterizing disease progression in adrenoleukodystrophy
- Evaluating endpoints for clinical trials
- Supporting regulatory discussions
Canavan Disease Registry:
- Natural history data collection
- Patient outcomes tracking
- Clinical trial readiness
CureYLD partners with leading academic medical centers including:
- Boston Children's Hospital
- University of Minnesota Leukodystrophy Center
- Children's Hospital of Philadelphia (CHOP)
- University of California, San Francisco
¶ Leadership and Governance
CureYLD is led by a dedicated team with expertise in rare disease research, drug development, and patient advocacy:
- Scientific Advisory Board: Composed of leading researchers in leukodystrophy biology and gene therapy
- Clinical Advisory Board: Includes neurologists and pediatric specialists with extensive experience in leukodystrophy care
- Patient Advocacy Council: Ensures patient perspectives inform all organizational decisions
As a nonprofit organization, CureYLD relies on diverse funding sources:
- Private foundations and charitable donations
- Individual supporters and family foundations
- Pharmaceutical partnership agreements
- Government research grants
Annual reports and financial statements are publicly available, ensuring donors and stakeholders can track the organization's impact and resource allocation.
¶ Impact and Achievements
CureYLD serves as a vital resource for the leukodystrophy community:
- Patient navigation services: Helping families understand diagnosis, treatment options, and clinical trial opportunities
- Educational resources: Providing up-to-date information on disease mechanisms and therapeutic approaches
- Family support programs: Connecting affected families with resources and each other
- Advocacy efforts: Working with policymakers to increase awareness and funding for leukodystrophy research
Since its founding in 2019, CureYLD has:
- Funded over $15 million in leukodystrophy research
- Supported 12 active research programs
- Helped advance 3 programs toward clinical development
- Established partnerships with 8 academic institutions
- Built a patient registry with over 500 enrolled families
- 2020: Launched first research grant program
- 2021: Established clinical advisory board
- 2022: Initiated first IND-enabling studies for CY-001
- 2023: Entered first pharmaceutical partnership
- 2024: Expanded pipeline to 5 active programs
¶ Partnerships and Collaborations
CureYLD collaborates with leading research institutions:
- Harvard Medical School: Gene therapy vector development
- University of Pennsylvania: Canavan disease research
- University of Michigan: Biomarker discovery
- Stanford University: Small molecule screening
Strategic alliances with pharmaceutical companies support clinical development:
- Manufacturing partnerships for clinical supply
- Regulatory expertise for IND submissions
- Commercial development planning
CureYLD works closely with patient advocacy groups:
- United Leukodystrophy Foundation (ULF)
- MLD Foundation
-ALD Connect
- Canavan Disease Foundation
Looking ahead, CureYLD is focused on:
- Advancing the clinical pipeline: Moving CY-001 and subsequent programs into clinical trials
- Expanding research portfolio: Identifying and funding new therapeutic approaches
- Building clinical infrastructure: Establishing sites capable of conducting leukodystrophy clinical trials
- International expansion: Extending reach to serve patients globally
- Platform development: Creating tools and resources to accelerate all leukodystrophy programs